We showed that melanoma patients who were responsive to anti-PD-1 expressed significantly higher levels of TAP1, TAPASIN, LMP2, but not TAP2, compared to those who were not responsive to this therapy (Figure 4A). This evidence concerns the gene PSMB9 and melanoma.